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Abstract: Denopamine， which is an oral1y effective cardiotonic agent and a beta-1 
receptor-selective agonist， reportedly prolongs the survival of the BIO 14.6 strain of 
cardiomyopathic Syrian hamsters (BIO). The latter is an animal model of human idiopath. 
ic cardiomyopathy. . The purpose of t)1e present experiment was to investigate the effects 
of denopamine on myocardial damage in BIO hamsters. They were divided into two 
groups: one that received denopamine treatment (1 mg/kg/day) from 2 months of age， and 
a control (untreated) group. Morphological studies of the myocardium， assays for beta 
adrenergic receptors， and measurements of myocardial adenylate cyclase (AC) activity and 
cAMP concentration were performed at 1， 3， and 7 months of age in al1 animals. It was 
observed that denopamine: 1) inhibited the progression of disease from the stage of 
hypertrophy to that of congestive failure that was demonstrated in the control BIO hamster， 
2) inhibited the down-regulation of beta-1-adrenergic receptors in the myocardium of the 
control BIO hamsters at 7 months of age， and 3) prevented an increase in myocardial AC 
activity and cAMP concentration that was seen in control BIO hamsters at3 months of age 
(stage of early hypertrophy). In conclusion， denopamine may prevent myocardial damage 
in BIO hamsters by inhibiting the down-regulation of beta-1-adrenergic receptors， thus 
preventing an increase in myocardial AC activity and cAMP concentration 
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INTRODUCTION 
The BIO 14.6 strain of cardiomyopathic Syrian hamster (BIO) is a useful model of the 
idiopathic cardiomyopathy that occurs in humans. This strain develops spontaneous ca子
diomyopathy with myocardial necrosis， fibrosis， and calcification at 1 or 2 months of age， 
fol1owed by cardiac hypertrophy and congestive heart failure. This disorder is transmitted as 
an autosomal recessive trait 1)2)3)4). Sole et a].5)6) reported that the rate of cardiac norepine. 
phrine synthesis and metabolism was increased in the BIO hamster， and that dopamine 
accumulated in the middle layer of the ventricular muscle. Karliner et a].7) reported the number 
of alpha-1 and beta-adrenergic receptors to be higher in the BIO hamsters than in the control 
animals. These reports suggest that sympathetic nervous system abnormalities may be linked 
to the development of cardiomyopathy in the BIO hamster. 
Denopamine ((一〉一α一(3，4-dimethoxyphenethylaminomethyl)-4-hydroxybenzylalcohol) is a 
phenylethanolamine derivative that is orally administered as a cardiotonic agent. Clinical and 
experimental studies suggest that denopamine exerts a positive inotropic action in doses that 
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do not significant1y influence the blood pressure or pulse rate8)9)lO). Denopamine is a selective 
agonist of the beta-1-receptorll). Its administration has been shown to prolong the survival of 
BIO hamsters (personal communication from Tanabe Seiyaku Co.， Ltd.， Osaka). We therefore 
hypothesized that denopamine may prevent myocardial damage in the BIO hamster via its 
involvement with the beta-adrenergic receptors. Accordingly， we investigated the effects of 
denopamine on myocardial damage by studying the morphology of the myocardium， the density 
of the beta-1-adrenergic receptors on the cardiac membrane， the activity of myocardial 
adenylate cyclase (AC)， and the concentrations of cAMP in BIO hamsters 
MATERIALS AND METHODS 
BIO hamsters (Shizuoka Laboratory Animal Co.， Ltd.， Shizuoka) were utilized. Two 
animals were placed in each cage and were divided into treated and control groups. Begining 
at the age of two months， the denopamine-treated hamsters were fed laboratory chow 
(Oriental Yeast Co.， Ltd.， Tokyo) that contained denopamine， at a daily adjusted dose of 1 mg 
/kg body weight. Control animals received chow without denopamine. Ten animals were 
sacrificed by exsanguination via an intra-aortic catheter and ventricles were excised at 1， 3， 
and 7 months of age respectively 
Morphological studies 
The ventricles were separated from the atria and fatty tissues and weighed. Staining with 
hematoxylin-eosin (HE)， Azan-Mallory， and p-aminosalicylic acid (P AS) was performed 
routinely using sections of the left ventricle in a half trans-sectional specimen. The sectional 
area of the left ventricular lumen， the percent area of myocardial fibrosis (area of fibrosis/ 
myocardium) and diameter of the myocyte were each measured with a color image processor 
(SPICCA I， Avionics Japan Co.， Ltd.， Tokyo). 
Membrane preparation 
Membrane fractions were prepared according to Van et al.12)， with some modifications. 
Briefly， ventricles were homogenized in an ice-cold 5 mM  Tris-HCl buffer (pH 7.4) that 
contained 1 mM  MgC12， 0.25 M sucrose， and 1 mM  phenylmethyl sulfonyl floride (PMSF) by 
using a Bio Mixer (Nihonseiki Co.， Ltd.， Tokyo). The homogenate was centrifuged at 400X 
g for 10 min and the supernatant was then centrifuged at 105，000 X g for 40 min at 40C. The 
resulting pellets were resuspended in ice-cold 50 mM  Tris-HCl buffer (pH 7.4) that contained 
10 mM  MgC12 and 1 mM  PMSF， and recentrifuged 105，000 X g for 20 min at 40C. The final 
pellets were resuspended in 50 mM  Tris-HCl buffer as described above. Each of the above 
steps was performed at 40C. Isolated membranes were used for receptor binding assays and AC 
activity assays. 
Assay for beta-adrenergic receptors 
Beta-adrenergic receptors were evaluated by the radioligand binding assay described by 
Williams et al.13)， with some modifications. Homogenates of the cardiac membrane were 
incubated with a range of concentrations of [3HJ -dihydroalprenolol ([3HJ -DHA) (N ew 
Research Products， Boston， MA， USA) (0.25-6 nM [3H]-DHA in a final volume of 200μ1) at 
3TC for 10 min. Each incubation was terminated by adding 15 ml of cold buffer (1 ml/sec for 
15 sec)， followed by rapid vacuum filtration through fiber glass filters (Whatman， GF /C， 
Whatman Internatinal Ltd.， Maidstone， England). The radioactivity of the membrane-bound 
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[3HJ-DHA was measured by liquid scintillation counting method. Nonspecific binding was 
determined by performing parallel assays in the presence of 1μM propranolol. Specific binding 
to beta-adrenergic receptors was defined as the difference between the total and nonspecific 
binding. Specific binding data were analyzed by Scatchard plots to determine the number of 
beta-adrenergic receptors present14). 
Measurement of cAMP concentration 
The concentration of cAMP was determined according to a previously described method15)16). 
Approximately 20 mg of heart muscle was frozen in liquid nitrogen immediately after excision. 
Frozen tissue was homogenized in approximately 100 volumes of ice-cold 6% trichloroacetic 
acid (TCA) by using a Bio Mixer. Homogenates were centrifuged at 3000 X g for 10 min at 4 
oc. The resulting supernatants were centrifuged three times at 3，000 X g for 5 min at 40C. Prior 
to each centrifugation， supernatants were mixed with ether-saturated water. A volume of 50 
μ1 of the final supernatant was succinylated by mixing with 45μ1 of succinic anhydride in 
dioxane and 5μ1 of triethylamine for 10 min at room temparature. Next， 400μ1 of 0.3 M 
imidazole buffer was added to this preparation. Following derivatization， 100μ1 of each sample 
was incubated with 100μ1 of 1251 -succinyl cAMP tyrosine methylester and 100μ1 of cAMP 
antiserum for 36 hours on ice. Any remaining 1251 -succinyl cAMP tyrosine methylester that did 
not bind to the cAMP antiserum was removed by passage through dextran-coated charcoal. 
Radioactivity was measured by using a gamma counter. Parallel assays with standard solu-
tions of cAMP were performed to obtain the standard curve. Concentrations of cAMP in the 
myocardium were quantitated by reference to this standard curve. The RIA kit used in these 
experiments was purchased from Yamasa Co.， Ltd. (Chiba). 
Adenylate cyclase activity assay 
Adenylate cyclase activity was determined according to the methods of Koji et al.!7l and Abe 
et a1.1B) with some modifications. Briefly， 90μg of the membrane fractions were incubated with 
50 mM  Tris-HCl buffer (pH 7.5) that contained 5 mM  MgCI2， 1 mM  Tris-EGT A， 2.5 mM  N a2 
adenosine triphosphate (ATP) ， and with or without 10-3M isoproterenol at 3TC for 5 min. 
The fractions were then centrifuged at 6，000 X g for 20 min at -40C. Concentrations of cAMP 
in the supernatants were measured as described above. The amount of cAMP synthesized from 
A TP was considered to represent the adenylate cyclase activity in membrane fractions 
Statistical analysis 
Data are expressed as the mean士SD. Differences between groups were analyzed by the 
Mann-Whitney method. A level of p < 0.05 was considered statistically significant. 
RESULTS 
Morphological自tudies
The weight of heart at 3 months of age significantly exceeded that at 1 month of age. 
However， no appreciable change in the weight of the heart was observed from 3 months of age 
to 7 months of age. The weight of the heart did not differ in the denopamine-treated vs. the 
control groups at 3 and 7 months of age (Table 1). 
The cross-sectional area of the left ventricular lumen at 3 months of age significantly 
exceeded that at 1 month of age in both groups. There were no significant differences in the 
cross-sectional area of the left ventricular lumen in both groups at 3 months of age. The cross 
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sectional area of the left ventricular lumen did not change between 3 and 7 months of age in 
the denopamine-treated group. The control group exhibited a significant increase in lumen 
area in the same period. Thus， the cross-sectional area of the left ventricular lumen in the 
control group significantly exceeded that of the denopamine-treated group at 7 months of age 
CTable 1). 
The diameter of the myocyte increased in the denopamine-treated and the control groups 
between 1 and 3 months of age. no appreciable changes in myocyte diameter occurred in the 
denopamine-treated group until 7 months of age. However， decreases in myocyte diameter 
were observed until the age of 7 months in the control group. Thus， the diameter of the 
myocyte in the control group was significantly less than that of the denopamine-treated group 
at 7 months CTable 2). 
The percent area of fibrosis increased significantly between 1 and 3 months of age in the 
denopamine-treated and control groups. However， at 7 months of age， this parameter in目
creased in the control group， but did not change in the denopamine-treated group. Thus， at 7 
months of age， the percent area of fibrosis was significantly greater in the control group 
relative to that in the denopamine-treated group CTable 2). 
Desity of beta -adrenergic receptors 
The density of the beta-adrenergic receptors was significantly higher at 3 months of age than 
that at 1 month of age in the denopamine-treated and control groups. The density of the beta 
adrenergic receptors significantly decreased in both groups between 3 and 7 months of age， 
with a more pronounced decrease occurring in the control group. Thus， at 7 months of age， the 
receptor density was lower in the control group than in the denopamine-treated group CTable 
3). 
Tabl巴l. H巴artweight and left ventricular lumen ar巴a
Heart weight (g) Left ventricular lumen area (mmり
Age 1M 3M 7M 
D 0.78士0.08" 0.80士0.07"
C 0.40土0.04 。.7土0.05" 0.79土0.08"
M， month of age目
D， denopamine-treated BIO 14.6 cardiomyopathic hamster 
C， control BIO 14.6 cardiomyopathic hamster 
1M 
2.27士1.70 
a) vs. C (lM)， p<0.05， b) vs..C (lM)， pく0.01，vs. C (3M) and D (7M)， p<0.05. 




Table 2. Myocyte diameter and area of fibrosis/myocardium ratio 
Myocyte diameter (μm) Area of fibrosis/myocardium ratio (%) 
Age 
D 
1M 3M 7M 1M 3M 7M 
16.51士0.70" 16.71士0.93"
C 11.31士0.70 17.00土1.86" 9.30土0.47b
M， month of age 
D， denopamine-treated BIO 14.6 cardiomyopathic hamst巴r
C， control BIO 14.6 cardiomyopathic hamster. 
a) vs. C (lM)， p<0.01， b) vs目 C(3M) and D (7M)， pく0.01，
c) vs. C (lM)， pく0.01，vs. C (3M) and D (7M)， p<0.05 
Data are expressed as the mean士SDof 10 hamsters 
3.09土1.63" 2.64土0.59'
0.45土0.26 4.54土1.82" 4.91土1.5" 
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At 3 months of age， the control group exhibited cAMP concentrations that were higher than 
at 1 month of age. However， the concentrations in the denopamine-treated group showed no 
appreciable changes from 1 to 3 months of age. Collectively， the cAMP concentrations in the 
control group were higher than those in the denopamine-treated group. Compared to the data 
at 3 months of age， the cAMP concentration was significantly increased in the denopamine 
treated group， and significantly decreased in the control group at 7 months of age. Taken 
together， at 7 months of age， the concentrations of cAMP in the control group were significant-
ly lower than those in the denopamine-treated group CTable 3). 
AC activity 
In the absence and presence of isoproterenol， AC activity in cardiac membranes was signifi-
cantly higher at 3 months of age than at 1 month of age in the control group. However， inthe 
denopamine-treated group， the AC activity was significantly lower at 3 months of age than at 
1 month of age with or without isoproterenol. The AC activity in the absence and presence of 
isoproterenol at 3 months of age was significantly higher in the control group vs. the 
denopamine-treated group. Regardless of isoproterenol， AC activity was decreased between 3 
and 7 months of age in the control group， and showed no changes from its 3 month value in the 
denopamine-treated group. Thus， AC activity at 7 months of age was lower in the control 
group vs. the denopamine-treated group CTable 4). 
Table 3. Density of beta-adrenegric receptors and cAMP concentration 
Density of beta -adrenergic receptors 
(fmol/mg of protein) 
Age 1M 3M 7M 1M 
D 20.0士2.4" 1.7土l.7b 
C 14.8土2.8 2.4土5.2" 6.9土2.4' 2.27士0.21
M， month of ag巴
D， denopamine-treated BIO 14.6 cardiomyopathic hamster 
C， control BIO 14.6 cardiomyopathic hamster. 
a) vs. C (1M)， p<O.Ol， b)vs. C (lM)， p<0.05， D (3M)， p<O.Ol， 
c) vs. C (3M)， pく0.01，d) vs. C (1M)， C (7M) and D (3M)， p<0.05， 
e) vs. C (lM)， C (7M) and D (3M)， p<0.05. 
Data are expressed as the m巴an土SDof 10 hamst巴rs
Table 4. Adenylate cyclase activity 
cAMP concentration 







Baseline activity Isoproterenol-stimulated activity 
(pmol/ mg/ min) 
Age 1M 3M 7M 
D 3l.1土6.7" 3.7土6.2'
C 4l.2土2.0 47.4土7.7b 2l.6土3.5a
M， month of age 
D， denopamine-treated BIO 14.6 cardiomyopathic hamster 
C， control BIO 14目6cardiomyopathic hamster. 
1M 
82.2士13.3
a) vs. C (1M)， p<0.05， b)vs. C (1M)， pく0.05，C (7M) and D (3M)， pく0.01，
c) vs. C (lM) and C (7M)， p<0.05. 







In this study， itwas observed that the cardiac musc1e of the control BIO hamster was 
hypertrophic at 3 months of age and exhibited evidence of severe heart failure at 7 months of 
age. It was also observed that the cardiac musc1e of the denopamine-treated BIO hamster was 
hypertrophic at 3 and 7 months of age. This indicates that denopamifle administration 
suppressed the disease progression from the stage of hypertrophy to that of congestive failure 
during cardiomyopathy in BIO hamsters. 
Previous studies have shown that sympathetic nervous system abnormalities may be associat回
ed with the development of cardiomyopathy in the BIO hamster5)6)7). Kobayashi et aP9) 
described increases in the number of beta-adrenergic and alpha-adren町 gicreceptors in BIO 
hamsters prior to hypertrophy. In addition， Ikegawa et aPO) showed increases in the number 
of these receptors before and during the early stage of hypertrophy. In this study， we observed 
the same changes in the beta-adrenergic receptor level at 3 months of age and a decrease in 
number at 7 months of age in both the denopamine-treated and the control BIO hamsters. 
However， there was a greater decrease in receptor number in the control BIO hamsters relative 
to those treated with denopamine. These data suggest that denopamine inhibits the down 
regulation of the myocardial beta-adrenergic receptors in BIO hamsters. 
This study demonstrated that， regardless of isoproterenol stimulation， AC activity and cAMP 
concentration were higher in control BIO hamsters than in denopamine-treated BIO hamsters 
at 3 months of age. This illustrates that denopamine suppresses the increase in AC activity and 
cAMP concentration that parallels the changes in beta-adrenergic receptor number seen in the 
early hypertrophy of this animal model. Taira et aPl) reported that in the isolated canine 
myocardium， the cAMP concentration required to stabilize cardiac musc1e contraction was 
lower during the administration of denopamine than of isoproterenol. Moreover， by using 
canine myocardium as well， Bing et a1.22) demonstrated that denopamine-stimulated AC 
activity was one-quarter of that obtained by equal concentrations of isoproterenol. These 
studies show that denopamine suppresses the increase in AC activity and cAMP concentration 
produced by isoproterenol. Stadel et aP3) reported that cAMP phosphorylates the beta 
adrenergic receptors via a cAMP-dependent protein kinase. These authors also found that AC 
activity was correlated with the phosphorylation of the beta-adrenergic receptors in turkey 
erythrocytes. Benovic et a1.24) further corroborated this by showing a positive correlation 
between AC activity and beta-adrenergic receptor kinase catalysis. It is possible that 
denopamine may prevent the down-regulation of beta-adrenergic receptors in the cardiac cel 
membranes in 7 month-old BIO hamsters by suppressing the elevation of AC activity and 
cAMP concentration. The prevention of the down-regulation of the beta-adrenergic receptors 
by denopamine may preserve the myocardial contractile response to catecholamines in the BIO 
hamster， even at 7 months of age. This may be a mechanism by which denopamine suppresses 
the progression froin hypertrophy to congestive failure in cardiomyopathic BIO hamsters. 
The elevated calcium levels found in the myocardium of pre-hypertrophic BIO hamsters are 
thought to be involved in various cardiac dysfunctions in these animals7)19). cAMP-dependent 
protein kinase A regulates L-type calcium channels， phospholamban， and troponin 1. Protein 
kinase A can cause a calcium overload by influencing these calcium-regulatory molecules in the 
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myocyte 25)27) Therefore， this study suggests that denopamine may prevent an increase in 
calcium concentrations by inhibiting the increase in cAMP concentrations early in the stage of 
cardiac hypertrophy in the BIO hamster. 
In this study， itwas concluded that denopamine may prevent myocardial damage in BIO 
hamsters by inhibiting the down-regulation of beta-l-adrenergic receptors， thereby preventing 
an increase in myocardial AC activity and cAMP concentration. . Thus， denopamine may be a 
benefical treatment for idiopathic cardiomyopathy 
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